Who is using the OmniPod® DASH in the Association of British Clinical Diabetologists (ABCD) Audit: An interim report of baseline characteristics TSJ Crabtree^{1,2}, M Haq³, E Gatdula⁴, N Hassan¹, J Varghese⁵, K Bull⁵, Å Lumb⁶, L Leelarathna⁷, P Narendran⁸, S Hussain⁹,



F Gibb¹⁰, P Hammond¹¹, P Choudhary¹², EG Wilmot^{1,2} on behalf of all ABCD Worldwide Omnipod Audit contributors

1. University Hospitals of Derby and Burton NHS Trust, UK; 2. University of Nottingham, UK; 3. Tunbridge Wells Hospital, UK; 4. University Hospital of Llandough, UK; 5. Stepping Hill Hospital, UK; 6. Oxford University Hospitals NHS Trust, UK; 7. Manchester University Hospitals NHS Trust, UK; 8. University Hospitals Birmingham NHS Trust; 9. King's College London, UK; 10. Edinburgh Royal Infirmary, UK; 11. Harrogate and District Hospitals NHS Trust, UK; 12. University Hospitals of Leicester NHS Trust, UK

The Omnipod DASH is a tubeless insulin pump and frequently used in UK clinical practice. Evidence comparing tubed vs tubeless pump systems is limited. Current evidence supports the use of the Omnipod systems and their efficacy in reducing HbA1c and improving quality of life in people with type 1 diabetes[1-3].

The ABCD Worldwide Omnipod audit launched in early 2022 with the aim of collecting data on the use of Omnipod patch insulin pump and provide insights into the real-world outcomes.

Methods

The ABCD Omnipod DASH audit collects routine clinical data using a secure online tool. Data is submitted to the audit from clinical teams. This analysis provides a cross-sectional report of current baseline data in the ABCD Omnipod DASH audit. tool using descriptive statistics. Data was processed and analysed in Stata 16. Data are reported as mean±SD or median (interguartile range).

References

- Lavne et al. 2016 JDST
- Danne et al. 2018 Paediatr Diabetes 2.
- 3. Polonsky et al. 2016 DTT

Table 1. Baseline characteristics of the ABCD Worldwide Omnipod audit cohort

Characteristic		
Age, years	Median (IQR)	36 (23-48)
Gender, female	% (n/N)	69.4 (100/144)
Ethnicity, white british	% (n/N)	95.8 (138/144)
HbA1c, mmol/mol	Mean±SD	66.8±15.3
Weight, kg	Mean±SD	74.3±20.2
BMI, kg/m2	Mean±SD	25.5±7.8
Total daily insulin dose, units	Mean±SD	46.8±23.5
Diabetes duration, years	Median (IQR)	19 (7-28.1)
Index of multiple deprivation (IMD), deciles	Median (IQR)	8 (6-9)
Aged <18 years, % (n)	11.8 (17/144)	
Total daily insulin dose>60units, % (n)	25% (36/144)	
Previous multiple daily injections, % (n)	32.6 (47/144)	

Conclusion

The ABCD Worldwide Omnipod audit includes data from a wide range of individuals. These baseline data provide interesting insights into technology. Of note, there may be implications from the data on socioeconomic status, ethnicity, total daily dose and indications for pump therapy.

ABCD Worldwide Omnipod The Audit is open for registration for both paediatric and adult centres. To register and learn more please follow the QR code below

Results

Presently 144 users have data entered into the secure online tool across 9 centres in the UK. The baseline (pre-Omnipod) characteristics are in the table above. Key findings include:

- Median index of multiple deprivation was 8 (6-9) with more individuals from nondeprived backgrounds (Chi-squared P=0.003), although this may be due to the characteristics of the registered centres.
- One third (32.6%,47/144) were new to pump therapy. If established on pump, median duration was 7.2 years (4-10.5)

- The most frequent indications for pump therapy were problematic hypoglycaemia (46/134, 34.3%) and HbA1c above target (37/134, 27.6%).
- flash/continuous Most (77.8%) use glucose monitoring
- 5 individuals were using closed-loop (DIY).
- Mean baseline total daily dose (TDD) was 46.8±23.5units at baseline: 25% of individuals have a TDD>60units

REGISTER HERE!!!

